RESUMEN

To clarify if one of the most common antihypertensive drugs, propranolol, can prevent venous thrombotic process, rats were treated with propranolol (PRO; 5 mg/kg i.p.) in an acute or chronic (14 days) manner. Both regimens resulted in a marked reduction of the systolic blood pressure (p < 0.001) and, probably as a consequence, in the shortening of the bleeding time (p < 0.01). After ligation of the vena cava, the incidence of the venous thrombosis and the thrombus weight decreased significantly in both propranolol-treated groups (p < 0.01) when compared to control rats. The antithrombotic effect of PRO was not accompanied by any changes in activated partial thromboplastin time, prothrombin time or euglobulin clot lysis time. However, long-term administfation of PRO resulted in a reduction of the ADP-induced platelet aggregation.

Asunto(s)

RESUMEN

Clinical and experimental data have recently accumulated for antithrombotic action of angiotensin-converting enzyme inhibitors (ACE-1s). We have shown previously that captopril (which contains a thiol group in the moiety) exerts more pronounced antithrombotic activity than does an equipotent dose of enalapril (the drug devoid of the thiol group). To clarify the relative importance of the presence of the thiol group in the molecule versus angiotensin-converting enzyme (ACE) inhibitory properties in the antithrombotic action of captopril, rats were treated with captopril (5 mg/kg twice daily; CAP), epicaptopril (stereoisomer of captopril devoid of ACE-inhibitory properties; 5 mg/kg twice daily; EPI), N-acetylcysteine (3.75 mg/kg twice daily; ACC), enalapril (3 mg/kg once daily; ENA), or distilled water (VEH) for 10 days, per os. After ligation of the vena cava, the incidence of the venous thrombosis and/or the thrombus weight decreased significantly in all but the ENA-treated groups when compared with control rats. The effect of CAP, EPI, and ACC was accompanied by a marked reduction of euglobulin clot lysis time and, with the exception of ACC, by an increase in prothrombin time in the blood collected from the site of the thrombus formation. Antithrombotic activity of EPI was completely abolished by nitric oxide synthase inhibitor N(G)-nitro-L-arginine methyl ester (L-NAME) or indomethacin, with the parallel reversal of fibrinolytic and coagulation parameters toward normal. Activated partial thromboplastin time, mean blood pressure, and bleeding time were not altered by either of the administered drugs. Thus, we demonstrated that thiol compounds exert antithrombotic activity by increasing fibrinolysis and/or suppression of the extrinsic pathway of the coagulation cascade in a nitric oxide/prostacyclin-dependent manner.

Asunto(s)

RESUMEN

In previous studies, we have shown that losartan possesses nitric oxide-dependent antithrombotic properties in various models of hypertension in rats. It was demonstrated that stimulation of AT2-receptors plays an important role in the pharmacological effects of AT1-receptor antagonists. Thus, in this study, we examine the participation of AT2-receptors in the antithrombotic action of losartan in renal hypertensive rats on venous thrombosis induced by a two-hour ligation of the vena cava. Losartan administration(30 mg/kg, p.o.) resulted in a marked decrease in thrombus weight (by 85%, p<0.001). PD123319, an AT2-receptor antagonist (10 mg/kg, i.v.), administered concomitantly with losartan, abolished its antithrombotic effect, whilst it had no influence on thrombus weight when given alone. A significant decrease in systolic blood pressure was observed in animals given losartan. PD123319 administration didnot abolish this action of losartan and did not alter blood pressure when given alone. No changes in prothrombin time, activated partial thromboplastin time, or euglobulin clot lysis time were observed in animals administered losartan and/or PD123319.Similarly, primary haemostatics evaluated by bleeding time and platelet count did not change in any group of rats. In conclusion, we have shown that AT2-receptor stimulation is involved in the antithrombotic action of losartan in renal hypertensive rats.

Asunto(s)

RESUMEN

Angiotensin-(1-7) [Ang-(1-7)] is the bioactive peptide which may be responsible for some of the pharmacological effects of losartan. Our previous study has demonstrated the antithrombotic action of losartan in a model of experimental thrombosis. In the present study, we compared the antithrombotic action of losartan and Ang-(1-7). Acute (10 mg/kg, p.o.) and chronic (10 mg/kg, p.o., three weeks) losartan administration to spontaneously hypertensive rats (SHR) induced a decrease in thrombus weight (1.6 +/- 0.6 mg and 1.2 +/- 0.3 mg respectively vs. control 2.9 +/- 0.8 mg; p<0.05, p<0.05). A similar reduction was observed in two-kidney, one-clip hypertensive rats (2K-IC)receiving acute losartan administration (1.39 +/- 0.29 mg vs. 3.25 +/- 0.62 mg; p<0.01). Infusion of Ang-(1-7) to2K-lC rats also reduced the thrombus weight(1.01 +/- 0.34 mg, 1.23 +/- 0.38 mg and 2.17 +/- 0.36 mg for 1, 10, 100 pmol/kg/min, respectively vs. 3.58 +/- 0.6 mg control; p<0.01, p<0.01, p<0.05). Losartan produced a decrease in systolic blood pressure (BP) in SHR as well as in 2K-1C rats, while Ang-(1-7) infusion had no effect on BP. Acute losartan dosing to 2K-1C rats decreased platelet adhesion to fibrillar collagen(24.9 +/- 1.0% vs. control 31.5 +/- 1.1%, p<0.001). The incubation of platelet samples with Ang-(1-7) (10-6 and 10 5 M) also reduced adhesion to fibrillar collagen(38.4 +/- 0.1% and 33.8 +/- 0.8% respectively vs. control 40.0 +/- 0.6%; p<0.05, p<0.001). There were no apparent changes in prothrombin time, activated partial thromboplastin time and euglobulin clot lysis time in losartan and Ang-(1-7)-treated groups. We conclude that, like losartan, Ang-(1-7) is able to act as an antithrombotic agent.

Asunto(s)

RESUMEN

The potential antithrombotic action of losartan, an AT1 receptor antagonist, administered to two-kidney, one-clip rats (2K1C) in an experimental model of venous thrombosis was evaluated. The involvement of nitric oxide (NO) in this effect was also studied. Venous stasis was induced by ligation of the vena cava. Losartan after single dose (10 mg/kg, p.o.) significantly reduced the venous thrombus growth. The antithrombotic action of losartan in 2K1C rats was abolished by N(G)-nitro-L-arginine methyl ester (L-NAME, 30 mg/kg s.c.) and restored by L-arginine (1000 mg/kg s.c.). Platelet adhesion to fibrillar collagen significantly decreased after administration of losartan. No changes in primary hemostasis and platelet aggregation were observed. Moreover, coagulation parameters such as activated partial thromboplastin time, prothrombin time and euglobulin clot lysis time were found unchanged after losartan administration either in systemic circulation or at the place of thrombus formation. Our results indicate that antithrombotic activity of losartan in 2K1C rats is NO--dependent; observed inhibition of platelet adhesion could also play a role in this phenomenon.

Asunto(s)

RESUMEN

The potential antithrombotic action of losartan, the AT1 receptor antagonist, in an experimental model of venous thrombosis in spontaneously hypertensive rats (SHR) and Wistar Kyoto rats (WKY) was tested. The involvement of nitric oxide and prostacyclin in this effect was also studied. Venous stasis was induced by ligation of the vena cava. Losartan, after administration of a single, hypotensive dose (10 mg/kg, p.o.), significantly reduced the thrombus weight in SHR but not in WKY. The antithrombotic activity of losartan in SHR was abolished by NG-nitro L-arginine methyl ester (L-NAME) (30 mg/kg s.c.) but not by indomethacin (2.5 mg/kg s.c.). No changes in primary hemostasis, platelet aggregation, coagulation parameters such as activated partial thromboplastin time, prothrombin time, euglobulin clot lysis time, and fibrinogen level, either in SHR or in WKY rats, were found. Our results indicate the NO-dependent mechanism in the antithrombotic effect of losartan on venous thrombosis in SHR.

Asunto(s)

RESUMEN

Some cyclophosphamide toxic effects on lung tissue are presented. Cyclophosphamide metabolism, pathogenesis of lung damage and morphological lung tissue changes caused by that agent were characterized. Attention was focused on BAL evaluation as a useful method in the monitoring of lung tissue damage degree.

Asunto(s)

RESUMEN

Recent laboratory findings strongly suggest that renin-angiotensin system plays an important role in regulation of haemostasis and fibrinolysis. In our previous study we showed that captopril exerts antithrombotic effect in venous thrombosis in rats. In this study we demonstrated that this effect is not a result of changes in platelet count, fibrinogen level alterations in blood coagulation pathways and fibrinolytic activity of the plasma. Further investigations are necessary to elucidate the mechanism of antithrombotic action of captopril.

Asunto(s)

RESUMEN

Low density lipoprotein (LDL) form insoluble complex bonds with polymetacrylic and polyvinylsulphonic acids in the presence of calcium chloride. Quantity of arising complexes depends on the concentrations of LDL, acids and calcium chloride and on pH. These complexes dissociate solutions of sodium chloride, urea and guanidine hydrochloride.

Asunto(s)

RESUMEN

It was found that storing the plasma in the temperature 0 degree C, 4 degrees C and 20 degrees C and especially in 37 degrees C increases pH and decreases antiheparin activity estimated by the heparin-thrombin test. Measurements of the heparin-thrombin time should be carried out directly after obtaining the plasma or after reducing the plasma to pH 7.40.

Asunto(s)

Asunto(s)

RESUMEN

Antiheparin activity of plasma of different species of vertebrates depends to a large extent on contents of low density lipoproteins (LDL). High antiheparin activity of the blood plasma of chicken and human corresponds to high contents of LDL and low antiheparin activity of the blood plasma of horse, cow, sheep, dog and pig corresponds to decreased contents of these proteins. Differences in the contents of fibrinogen, acid alfa1-glycoproteins, globulins, alkaline proteins and antithrombin III activity have smaller influence on antiheparin activity in the blood plasma of the examined animals.

Asunto(s)

RESUMEN

Low density lipoproteins/LDL/ form unsoluble complexes with heparin of different molecular weight in the presence of CaCl2. Quantity of the complexes depends on molecular weight of heparin, concentration of reagents and pH of the reacting medium. The biggest quantity of complexes result from LDL-heparin of the molecular weight 16000, the quantity is smaller with heparin of the molecular weight 5100 and the quantity is smallest with heparin of the molecular weight 3700. Components of LDL--heparin complexes are bound by means of ion and hydrogen bonds.

Asunto(s)

RESUMEN

Quantity of unsoluble LDL complexes with heparin of different molecular weight in hypo-, normo-, and hyperlipemic blood serum in the presence of CaCl2 was estimated. At the same weight concentration the biggest quantity of LDL complexes are formed with heparin with heparin of the molecular weight 16000, the quantity is smaller with heparin of the molecular weight 5100, and it is the smallest with heparin of molecular weight 3700.

Asunto(s)

RESUMEN

Anti-heparin activity correlated with LDL concentration in the plasma. Blood plasma of women in labour is characterized by the high antiheparin activity and low LDL levels. Anti-heparin activity is low and LDL levels are low in blood plasma in childhood. An effect of other factors neutralizing heparin (e.g. fibrinogen, platelet factor 4, acid alpha 1-glycoprotein, globulins, basic proteins) and differences of anti-thrombin III on plasma anti-heparin activity has been excluded. Neutralization of heparin anticoagulation activity by LDL is of clinical value. Blood LDL level should be considered, while heparin therapeutical doses are under scrutiny.

Asunto(s)

Asunto(s)

Asunto(s)

Asunto(s)

Asunto(s)

RESUMEN

It was shown that increased antiheparin activity of the blood plasma of women in labour is evoked by increased level of low density lipoproteids (LDL). This activity does not depend on changes neither of the level of other compounds neutralizing heparin (fibrinogen, acid alpha 1-glycoproteid, globulins, basic proteins) nor conditioning its action (antithrombin-III). The intensity of antiheparin action of LDL increases in the presence of calcium ions.

Asunto(s)